151 related articles for article (PubMed ID: 23444985)
1. Feasible concomitant treatment with eltrombopag and oral anticoagulation in a patient with chronic immune thrombocytopenia and severe cardiac comorbidities.
Sanchez-Gonzalez B; Ancochea A; Garcia-Pallarols F; Jimenez C; Pedro C; Besses C
Platelets; 2014; 25(4):309-10. PubMed ID: 23444985
[No Abstract] [Full Text] [Related]
2. Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities.
Baldini S; Rigacci L; Carrai V; Fjerza R; Alterini R; Bosi A
Platelets; 2013; 24(3):242-3. PubMed ID: 22646237
[No Abstract] [Full Text] [Related]
3. Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment.
Cantoni N; Heizmann M; Bargetzi M
Br J Haematol; 2012 Jun; 157(5):639-41. PubMed ID: 22329466
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
5. Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura.
Fozza C; Pardini S; Marras T; Longu F; Isoni A; Contini S; Longinotti M
Ann Hematol; 2014 May; 93(5):899-900. PubMed ID: 24081576
[No Abstract] [Full Text] [Related]
6. Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.
Mahat U; Talati R; Kodish E
Pediatr Blood Cancer; 2019 Jun; 66(6):e27706. PubMed ID: 30854752
[No Abstract] [Full Text] [Related]
7. Treatment of chronic immune thrombocytopenia in children with romiplostim.
Chaturvedi S; McCrae KR
Lancet; 2016 Jul; 388(10039):4-6. PubMed ID: 27103125
[No Abstract] [Full Text] [Related]
8. Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
Zimrin A; Chumsri S
Ann Hematol; 2013 Aug; 92(8):1145-6. PubMed ID: 23328792
[No Abstract] [Full Text] [Related]
9. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
10. High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia.
Seidel MG; Urban C; Sipurzynski J; Beham-Schmid C; Lackner H; Benesch M
Br J Haematol; 2014 May; 165(3):419-21. PubMed ID: 24484542
[No Abstract] [Full Text] [Related]
11. [Successful management of primary immune thrombocytopenia with romiplostim during open heart surgery in a hemodialysis patient].
Nishikii H; Kurita N; Kusakabe M; Yokoyama Y; Kato T; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
Rinsho Ketsueki; 2019; 60(1):28-32. PubMed ID: 30726820
[TBL] [Abstract][Full Text] [Related]
12. Management of immune thrombocytopenia--something old, something new.
George JN
N Engl J Med; 2010 Nov; 363(20):1959-61. PubMed ID: 21067388
[No Abstract] [Full Text] [Related]
13. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
14. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
Al-Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J
Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
[No Abstract] [Full Text] [Related]
15. Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Perera M; Suarez A; Luzardo H; Lopez J; Molero T
Ann Hematol; 2012 Sep; 91(9):1497-8. PubMed ID: 22373551
[No Abstract] [Full Text] [Related]
16. Remissions after long-term use of romiplostim for immune thrombocytopenia.
Marshall AL; Scarpone R; De Greef M; Bird R; Kuter DJ
Haematologica; 2016 Dec; 101(12):e476-e478. PubMed ID: 27587382
[No Abstract] [Full Text] [Related]
17. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
Veneri D; Soligo L; Pizzolo G; Ambrosetti A
Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
[No Abstract] [Full Text] [Related]
18. Update on romiplostim and eltrombopag indirect comparison.
Cooper K; Matcham J; Helme K; Akehurst R
Int J Technol Assess Health Care; 2014 Jan; 30(1):129-30. PubMed ID: 24485057
[No Abstract] [Full Text] [Related]
19. Immune thrombocytopenia during childhood: new approaches to classification and management.
Buchanan GR
J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
[No Abstract] [Full Text] [Related]
20. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim.
Beck JC; Burke MJ; Tolar J
Pediatr Blood Cancer; 2010 Mar; 54(3):490-1. PubMed ID: 19908296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
